The U.S. Supreme Court unanimously ruled for Hikma Pharmaceuticals in its “skinny label” patent case involving a generic version of Amarin’s Vascepa. The Court said Hikma’s generic did not infringe Amarin’s patents, overturning a lower-court decision. The ruling strengthens the legal pathway for generic manufacturers to market drug copies limited to non-infringing indications while using cheaper labeling strategies. It also affects how generic companies handle inducement arguments tied to marketing language. In the background, Vascepa was originally approved for severe hypertriglyceridemia, with later FDA label expansion for less-elevated triglycerides and cardiovascular risk reduction. Amarin reported $214 million in Vascepa sales last year.